Attendees at our October 12 webinar had the invaluable opportunity to gain firsthand insights from two global authorities in the field of pulmonary hypertension. These distinguished experts, both co-authors of the 2022 European Society of Cardiology and European Respiratory Society clinical guidelines on pulmonary hypertension, shed light on the updated treatment algorithm outlined in the guidelines.
Panelists
- Prof. Marius Hoeper, Deputy Director of Respiratory Medicine at the Hannover Medical School, Germany
- Prof. Olivier Sitbon, Professor of Respiratory Medicine at the Paris-Saclay University, France
Moderator:
Robert Pleticha of admedicum, experts in Patient Engagement and Access
Learning objectives
- Pulmonary Arterial Hypertension (PAH) versus other forms of Pulmonary Hypertension
- The role of risk stratification in the management of patients with PAH
- Treatment strategies at the time of diagnosis and follow-up, including the role of comorbidities
- Perspective of new treatment modalities
Summary
Prevalence and Misconceptions about Pulmonary Hypertension:
- It’s emphasized that pulmonary hypertension, contrary to common belief, is not rare, affecting approximately 1% of the adult population worldwide.
- The prevalence is primarily driven by common forms of pulmonary hypertension, such as left heart disease and lung disease (WHO Groups II and III).
- Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension (CTEPH) are rare forms (WHO Groups I and IV.)
Diagnostic Approach:
- Highlighting the challenges in detecting pulmonary hypertension and differentiating between its types.
- The diagnostic algorithm focuses on unexplained dyspnea, starting from general practitioners to echocardiography and right heart catheterization.
Risk Assessment in Pulmonary Hypertension:
- Risk classification (low, intermediate, high) is based on the estimated mortality risk within one year.
- A complex set of variables is used for risk assessment, including noninvasive markers like the WHO functional class, six-minute walk distance, and BNP levels.
Treatment Strategies for Pulmonary Arterial Hypertension (PAH):
- General Measures
- Exercise training, psychosocial support, diuretics, oxygen therapy, and iron status correction.
- Calcium Antagonists: for patients showing positive vasoreactivity.
- Combination Therapies:
- Low or Intermediate Risk: Initial combination therapy with a PDE-5 inhibitor and an endothelin receptor antagonist.
- High Risk: Triple combination therapy including intravenous or subcutaneous prostacyclin.
- Follow-up Management: Regular risk reassessments to modify treatment.
New Developments
- Sotatercept:
- Sotatercept, an activin receptor ligand trap, shows promise in clinical trials.
- Demonstrated benefits in hemodynamics, exercise capacity, and reduction in clinical worsening events.
- Side effects include epistaxis, increased hemoglobin, and telangiectasia.
Clinical Implementation
- Discusses how healthcare professionals are adopting the new guidelines, with emphasis on pulmonary hypertension specialists driving treatment decisions.
- Future of PH Treatments:
- Speculation on the potential reduction in the need for lung transplantation and intravenous therapies with new treatments.
- The future role of sotatercept in treatment algorithms.
Concluding Remarks
The webinar effectively provides a comprehensive overview of the current and future landscape of pulmonary hypertension management. It underscores the importance of early detection, risk assessment, and the integration of new treatments like sotatercept in improving patient outcomes. The Q&A session further enriches the understanding of these concepts, offering insights into practical aspects of pulmonary hypertension management and future directions in treatment strategies.